- Home
- SCNI vs PCSA Comparison
SCNI vs PCSA Comparison
Compare SCNI & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- PCSA
- Stock Information
- Founded
- SCNI 2003
- PCSA 2011
- Country
- SCNI Israel
- PCSA United States
- Employees
- SCNI N/A
- PCSA N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- PCSA Health Care
- Exchange
- SCNI Nasdaq
- PCSA Nasdaq
- Market Cap
- SCNI 2.8M
- PCSA 2.8M
- IPO Year
- SCNI N/A
- PCSA N/A
- Fundamental
- Price
- SCNI $2.85
- PCSA $0.30
- Analyst Decision
- SCNI
- PCSA Strong Buy
- Analyst Count
- SCNI 0
- PCSA 1
- Target Price
- SCNI N/A
- PCSA $6.00
- AVG Volume (30 Days)
- SCNI 10.1K
- PCSA 2.5M
- Earning Date
- SCNI 05-14-2025
- PCSA 05-09-2025
- Dividend Yield
- SCNI N/A
- PCSA N/A
- EPS Growth
- SCNI N/A
- PCSA N/A
- EPS
- SCNI 8.20
- PCSA N/A
- Revenue
- SCNI $452,000.00
- PCSA N/A
- Revenue This Year
- SCNI N/A
- PCSA N/A
- Revenue Next Year
- SCNI N/A
- PCSA N/A
- P/E Ratio
- SCNI $0.34
- PCSA N/A
- Revenue Growth
- SCNI N/A
- PCSA N/A
- 52 Week Low
- SCNI $2.23
- PCSA $0.24
- 52 Week High
- SCNI $8.92
- PCSA $3.31
- Technical
- Relative Strength Index (RSI)
- SCNI 34.84
- PCSA 23.78
- Support Level
- SCNI $2.64
- PCSA $0.36
- Resistance Level
- SCNI $2.86
- PCSA $0.41
- Average True Range (ATR)
- SCNI 0.25
- PCSA 0.06
- MACD
- SCNI -0.06
- PCSA -0.00
- Stochastic Oscillator
- SCNI 35.93
- PCSA 24.18
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).